Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22797534 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CHRNA7GAABCHEABCB1 | |
| SCHEMBL24673919 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CHRNA7GAABCHEABCB1 | |
| SCHEMBL22797520 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CHRNA7GAABCHEABCB1 | |
| SCHEMBL24673802 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CHRNA7GAABCHEABCB1 | |
| SCHEMBL22797519 | 0.81 | OPRM1 (0.36) | ALDH1A1BCHEKMT2AMEN1 | |
| SCHEMBL22797533 | 0.81 | OPRM1 (0.36) | ALDH1A1BCHEKMT2AMEN1 | |
| SCHEMBL22799523 | 0.80 | ALDH1A1 (0.53) | ALDH1A1CHRNA7GAABCHETDP1 | |
| SCHEMBL22799896 | 0.80 | ALDH1A1 (0.53) | ALDH1A1CHRNA7GAABCHETDP1 | |
| SCHEMBL22798485 | 0.79 | OPRM1 (0.35) | ALDH1A1BCHEKMT2AMEN1 | |
| SCHEMBL22335650 | 0.76 | ALDH1A1 (0.52) | ALDH1A1GAABCHETDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-01 | — | — | US | disclosed |
| WO-2020249663-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | NME2, SLC28A1, SLC28A2 | ALDH1A1 248/4885CHRNA7 4531/4885GAA 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.